BridgeBio Pharma reported $71.5 million in net product revenue for its drug Attruby in the second quarter of 2025, slightly exceeding market expectations. The drug's launch in the U.S. is accelerating, with 3,751 unique patient prescriptions written by 1,074 prescribers as of August 1, 2025, up from 2,072 prescriptions by 756 prescribers in late April. The company added approximately 120 new patients per week in the 14 weeks following the previous update, driven primarily by new (naive) patients despite competition affecting experienced patient market share. Analysts from Piper Sandler, Mizuho, and Bank of America have expressed positive views on Attruby's performance, with price targets ranging from $58 to $76. Bank of America reiterated a Buy rating and increased its price target to $58, citing the drug's accelerating sales and positive implications for BridgeBio's pipeline. Meanwhile, BioXcel Therapeutics announced a publication on the effects of dexmedetomidine, the active ingredient in its drug BXCL-501, on stress-mediated behaviors in non-clinical studies. BioMarin also reported promising early results for a potential successor to its drug Voxzogo.